Jane Searfoss was inspired to become a child life specialist at Boston Children's Hospital because of her own experience ...

Wearable devices can identify, differentiate, and predict flare-ups, or the worsening of symptoms and inflammation, in inflammatory bowel disease (IBD), Mount Sinai researchers have shown in a ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory ...

Mirikizumab is a humanized immunoglobulin G4 monoclonal antibody that selectively binds to the p19 subunit of human interleukin (IL)-23.

The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success ...

First, I won a Summer Shred bodybuilding qualifier in August. When I showed up to the Championship in November, I weighed 215 pounds, with a 4.9 to 5.3 percent body fat estimate, according to an ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

This story was originally published in ProPublica, a Pulitzer Prize-winning investigative newsroom. Sign up for The Big Story ...

Eli Lilly has received approval from the US Food and Drug Administration (FDA) for Omvoh (mirikizumab-mrkz) to treat ...

Indianapolis: Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has approved Omvoh ...

Eli Lilly and Co. (LLY) announced that the U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment ...